Breaking News

DSM to Manufacture Novacta Compound for Trials

DSM BioSolutions has entered into an agreement with Novacta Biosystems Ltd. for the process development and cGMP production of its C. difficile molecule, a new class of lantibiotic compounds.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

DSM BioSolutions has entered into an agreement with Novacta Biosystems Ltd. for the process development and cGMP production of its C. difficile molecule, a new class of lantibiotic compounds. DSM has successfully completed the process development and began cGMP manufacturing of the Novacta compound at its microbial fermentation biotech facility in Capua, Italy. The product will initially be used for preclinical and Phase I trials. Villaume Kal, vice president of DSM BioSolutions said, &#8...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters